Insights From the Largest Global Precision Medicine Trial in NSCLC: The National Lung Matrix Trial

Insights From the Largest Global Precision Medicine Trial in NSCLC: The National Lung Matrix Trial

Publication date: Sep 11, 2019

First results from the National Lung Matrix Trial (NLMT), the largest global precision medicine trial in non-small cell lung cancer (NSCLC), showed that the probability of success with respect to achieving a clinically relevant objective response rate (ORR) in patients treated with crizotinib was very high for those with disease characterized by ROS1 gene fusions and a MET exon 14-skipping mutation – but the response was not as evident in those with NSCLC characterized by a MET amplification.

The NLMT (ClinicalTrials. gov Identifier: NCT02664935) is a multidrug, phase 2 study of adaptive design consisting of multiple single arms, each evaluating targeted therapy in a cohort of adult patients with NSCLC characterized by the presence of 1 or more specific actionable molecular alteration(s) as detected by a specific targeted sequencing panel.

Interim efficacy analyses conducted in other study cohorts, such as patients with disease characterized by an NF1 mutation receiving the MEK inhibitor selumetinib, in combination with docetaxel (16 individuals); and the cohort of patients with NSCLC characterized by the double LKB1/KRAS mutation who were treated with the mTOR inhibitor, vistusertib (23 individuals); met the criteria for study continuation.

However, the arm of the study evaluating vistusertib in the cohort of patients with disease characterized by a single mutation in LKB1 was closed following an interim analysis of efficacy.

Concepts Keywords
Adaptive Design Progression-free survival
Barcelona ROS1
Cancer Non-small-cell lung carcinoma
CDK4 MEK inhibitor
Cohort Piperidines
DCB Tyrosine kinase receptors
Docetaxel Antineoplastic drugs
Inhibitor Lung cancer
KRAS Chloroarenes
Lung Aromatic compounds
Median Organic compounds
Middleton Chemical compounds
Mutation Lung Cancer
NF1 NSCLC
Probability
Sequencing
Spain
Targeted Therapies
Targeted Therapy

Semantics

Type Source Name
disease DOID NSCLC
disease MESH non-small cell lung cancer
pathway BSID Non-small cell lung cancer
drug DRUGBANK Spinosad
drug DRUGBANK Crizotinib
disease MESH Lung Cancer
disease DOID Lung Cancer
gene UNIPROT KIDINS220
drug DRUGBANK Dichlorobenzene
gene UNIPROT CDK4
drug DRUGBANK Palbociclib
gene UNIPROT KRAS
gene UNIPROT NF1
drug DRUGBANK Selumetinib
drug DRUGBANK Docetaxel
gene UNIPROT STK11
drug DRUGBANK Vistusertib
drug DRUGBANK Methionine
gene UNIPROT SLTM
gene UNIPROT MET
gene UNIPROT SET
disease MESH cancer
disease DOID cancer

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *